The noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) elicited objective response rate (ORR) of 81.6% (95% CI, 76.5%–85.9%) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)…
BRUIN Final Analysis: Pirtobrutinib Durable in Post-Covalent BTK CLL/SLL | Targeted Oncology
